Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake ...

Lebanon: A recent study analyzing data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) has ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Discover Mounjaro Tirzepatide's impact on obesity in India post its March launch. Get insights on effectiveness against ...

and falsely claiming to sell ‘personalised’ compounded tirzepatide.” Mochi Health, which also develops a compounded version of Novo Nordisk’s GLP-1RA semaglutide, did not immediately ...